Results 111 to 120 of about 13,427 (242)

The intriguing possibility of using probiotics in allergen-specific immunotherapy. [PDF]

open access: yesWorld Allergy Organ J, 2023
Furci F   +4 more
europepmc   +1 more source

Allergic Rhinitis and Its Impact on Asthma (ARIA)‐EAACI Guidelines—2024–2025 Revision: Part II—Guidelines on Oral and Ocular Treatments

open access: yesAllergy, EarlyView.
ABSTRACT Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments.
Rafael José Vieira   +230 more
wiley   +1 more source

Attenuation of allergen-specific immunotherapy for atopic dermatitis by ectopic colonization of Brevundimonas vesicularis in the intestine. [PDF]

open access: yesCell Rep Med, 2023
Liu X   +12 more
europepmc   +1 more source

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS)

open access: yesAllergy, EarlyView.
In this prospective birth cohort from Munich, comprehensive clinical assessments and longitudinal lifestyle questionnaires were combined with cord blood immune profiling. Infants who later developed AD showed altered cord blood immune signatures, including reduced CD4+ T cells, increased B cells and markedly decreased Breg cells. Epidemiologic factors,
S. Preis   +14 more
wiley   +1 more source

Mechanisms and biomarkers of successful allergen-specific immunotherapy. [PDF]

open access: yesAsia Pac Allergy, 2022
López JF   +12 more
europepmc   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

open access: yesAllergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang   +37 more
wiley   +1 more source

Identification of key genes and the pathophysiology associated with allergen-specific immunotherapy for allergic rhinitis. [PDF]

open access: yesBMC Immunol, 2023
Fan K   +10 more
europepmc   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma ...
Saskia Carstensen‐Aurèche   +8 more
wiley   +1 more source

Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

open access: yesClinical &Experimental Allergy, Volume 55, Issue 3, Page 226-238, March 2025.
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bernardo Sousa‐Pinto   +121 more
wiley   +1 more source

Home - About - Disclaimer - Privacy